INTRODUCTION
With the widespread use of orthobiologics in everyday practice, attention must be directed to substantiate the evidence for their current use and to direct future practice guidelines. In any bioengineered environment, three components are required to provide the necessary biologic milieu for cell regeneration and renewal. The presence of stem cells, growth factors, and a biologic scaffold are integral to this process. Bone marrow aspirate (BMA) has been utilized as a source of bone marrow-derived mesenchymal stem cells (BM-MSC) with its relative ease of harvest, low morbidity, and feasible cost. BMA alone has a relatively low percentage of MSCs with only 0.001% to 0.01% of all nucleated cells in BMA being MSCs [1] . Therefore, the aspirate is typically concentrated by centrifugation in order to increase the ratio of MSCs. Concentrated bone marrow aspirate (cBMA) provides both stem cells and growth factors and relies on the host tissue to provide scaffold. The use of cBMA has become an increasingly popular alternative and adjunct in the treatment of cartilaginous lesions, bony defects, and tendinous injuries. Despite both basic science and clinical evidence of its efficacy, recent literature suggests that cBMA has different functions and roles in each biologic environment. Evidence suggests that stem cells act to direct local cells to stimulate regeneration and repair that is specific to each tissue. This process is mediated by secretomes from the stem cells, which allow their adaptation in each environment and therefore provides the appropriate growth factors and cytokines necessary to stimulate each tissue in a different fashion [2] . Growth factors derived from cBMA may be required for cell lineage differentiation although the exact growth factors have not to date been fully elucidated. The available literature regarding the use of cBMA in different tissue repair is highly heterogeneous with regards to indications, concentrations and overall functional outcomes.
This review attempts to examine the evidence behind the use of cBMA in cartilage, bone, and tendon regeneration and repair and to establish proof of concept for the use of cBMA in these biologic environments. In addition our systematic review will provide the reader with a reference of the level and quality of evidence of the current available literature evaluating the uses of cBMA in the treatment of lesions in cartilage, tendon, and bone.
MATERIALS AND METHODS
A systematic review was conducted according to PRISMA guidelines [3] . The following search terms were used in MEDLINE, EMBASE, and Web of Science databases on November 22, 2016: "cBMA OR concentrated bone marrow aspirate OR BMC OR bone marrow concentrate OR bone marrow derived mesenchymal stem cells". This was paired with one of the following search strategies: (1) "cartilage OR chondrocytes OR chondrogenesis OR arthritis OR osteoarthritis OR osteochondral OR chondral"; (2) "tenocytes OR tendon OR tendinitis OR tendinosis OR tendinopathy"; or (3) "bone OR bone healing OR malunion OR delayed union OR osteocyte OR osteogenesis". Inclusion criteria were: (1) clinical studies demonstrating the effect of cBMA in cartilage, bone; or tendon (2) published in peer-reviewed journal; and (3) written in English. Exclusion criteria included review articles, case reports, basic science studies, and studies evaluating additional pathologic processes. Two independent reviewers performed the literature search screening both title and abstract for all results. Potentially eligible studies received a full text review. The reference list of the identified articles in the results were manually screened for additional articles. A senior author was consulted if a consensus could not be reached. The following information was extracted and recorded from the included studies: Number of patients, preparation method of cBMA, cell count, treatment groups, adjunctive therapies/scaffolds, follow-up, objective and subjective outcomes, and level of evidence.
RESULTS
The initial literature search resulted in 1202 total studies. Once duplicates were removed and articles were screened for inclusion/exclusion criteria, 135 were included and full texts were assessed for eligibility. A total of 36 studies met inclusion/exclusion criteria and were included in this review.
Study characteristics
Thirty-one of 36 (86%) studies reported the method of centrifugation and preparation of cBMA. Fifteen of 36 (42%) studies reported either a cell concentration or an increase from baseline. There were no studies that reported on the minimal number of colony forming units in which below that number, cBMA did not provide significant benefit. Twenty-one of 36 (58%) were level of evidence Ⅳ, 12/36 (33%) were level of evidence Ⅲ, and 3/36 (8%) were level of evidence Ⅱ. Two studies were industry funded while 37 declared no conflict of interest.
cBMA in full thickness cartilage lesions
Seven studies evaluated the effect of cBMA in the treatment of full thickness cartilage defects in the knee and all reported significant clinical improvement postoperatively summarized in Table 1 [4] [5] [6] [7] [8] [9] [10] . Three studies evaluated the effect of cBMA combined with microfracture and demonstrated improved clinical outcomes with reconstitution of original cartilage on magnetic resonance imaging (MRI). All three studies reported bone marrow edema and/or subchondral irregularities [4] [5] [6] . One study evaluated the effects of cBMA when compared with matrix-induced autologous chondrocyte implantation (MACI) and found that patients receiving cBMA had a significantly improved IKDC subjective score (P = 0.015) with 81% complete cartilage filling on MRI [7] . One study compared the effects of cBMA to PRP and reported that patients who received cBMA had T2 values closer to that of superficial hyaline cartilage (P = 0.01) [10] . Variation of cBMA application was seen amongst the studies evaluated. Several studies used cBMA in isolation, while other studies combined cBMA with either a collagen or hyaluronic acid scaffold. Many of these studies prepared the defect site and implanted cBMA through arthroscopic techniques.
cBMA in osteochondral lesions
Ten studies evaluated the effect of cBMA in the treatment of osteochondral defects in the talus (7/10) and the knee (3/10) summarized in Table 2 [2, [11] [12] [13] [14] [15] [16] [17] [18] [19] . All ten studies reported both clinical and radiologic improvements postoperatively after receiving cBMA. Six studies evaluated the effects of cBMA with no concomitant procedure and reported good clinical outcome scores including AOFAS, IDKS, and KOOS. For studies that utilized either a collagen or a hyaluronic acid scaffold, no significant difference was reported between the two groups. Buda [11] evaluated cBMA compared to autologous chondrocyte implantation (ACI) and reported no clinical difference between the two treatment strategies but found a higher presence of hyaline like values and lower incidence of fibrocartilage on T2 mapping in the cBMA group. One study favored treatment with cBMA when comparing cBMA to microfracture reporting 100% and 28% normal IDKC values at 5-year follow up, respectively [18] . Lastly, one study reported higher MOCART scores and T2 relaxation values with measurements resembling those of native cartilage in groups that received both microfracture with cBMA compared to groups that received microfracture alone [19] . cBMA had also been used as an adjunctive treatment to autologous osteochondral transplantation and resulted in overall improved FAOS scores post-operatively [2] . Variation of cBMA application was seen amongst the studies evaluated. These included the use of either a collagen powder or hyaluronic acid scaffold, with the majority of studies using arthroscopic techniques for cBMA implantation.
cBMA in osteoarthritis
Five studies evaluated cBMA in the treatment of knee osteoarthritis (OA) summarized in Table 3 [20] [21] [22] [23] [24] . Only two studies evaluated the efficacy of cBMA without an adjunctive procedure. One reported better clinical outcomes at one week and three months in patients who received cBMA but found no difference in these scores after six months [24] . One study reported significant clinical improvements but found that 76% of patients had abnormal International Cartilage Repair Society repair scores [23] . Three studies evaluated cBMA combined with either PRP or PRF and found functional and clinical improvements in the cBMA groups with improvement in cartilage repair, although not significant [20] [21] [22] . Variation of cBMA application was seen amongst the studies evaluated, which utilized ultrasound or fluoroscopy for needle placement or was performed under arthroscopic guidance.
cBMA in bone healing
Nine studies evaluated the use of cBMA in bone healing summarized in Table 4 [25 -33] . Eight of nine studies reported on the use of cBMA in either non-union or delayed union. One study demonstrated initial radiographic and functional improvements in the cBMA group, but reported similar outcomes after one year post-operatively [31] . All studies reported either lower or similar complication rates postoperatively in groups that received cBMA compared to groups receiving no additional treatment. Bone [7] Patellofemoral 
Results LOE
Buda et al [11] OCL of talus Scaffold was a hyaluronic acid membrane loaded with previously cultured chondrocytes (ACI) or with BMAC. Platelet rich fibrin gel was produced the day before surgery using Vivostat System 1 (vivolution A/S). Harvested and processed 120 mL of the patient's venous blood to obtain 6 mL of platelet rich fibrin gel. 60 mL BMA was harvested from posterior iliac crest using Smart PRepI to obtain 6 mL of BMAC. 1 g powder mixed with 2 mL BMAC and 1 mL platelet rich fibrin gel. The hyaluronic acid membrane was cut and loaded with 2 mL BMAC and 1 mL platelet rich fibrin gel. A layer of platelet rich fibrin gel was placed over the implant once in place to provide additional stability NS n (total) = 80: (1) [13] OCL of talus Scaffolds either: (1) porcine collagen powder SpongostanI Powder (J and J) mixed with autologous cell concentrate and platelet gel; or (2) hyaluronic acid membrane (fidia advanced biopolymers) with addition of platelet gel. Platelet rich fibrin gel was produced the day before surgery using Vivostat System 1 (vivolution A/S). Harvested and processed 120 mL of the patient's venous blood to obtain 6 mL of platelet rich fibrin gel. 60 mL BMA was harvested from posterior iliac crest using Smart PRepI to obtain 6mL of BMAC. 1 g powder mixed with 2 mL BMAC and 1ml platelet rich fibrin gel. The hyaluronic acid membrane was cut and loaded with 2 mL BMAC and 1 mL platelet rich fibrin gel. A layer of platelet rich fibrin gel was placed over implant once in place to provide additional stability NS n = 64. [16] OCL of talus One step arthroscopic transplantation. Platelet gel using Vivostat system. 60 mL BMA harvested from posterior iliac crest. Concentrated using SmartPReP in order to obtain 6 mL of concentrate. [17] OCL of talus Porcine collagen powder (J and J) or hyaluronic membrane scaffold. 60 mL of bone marrow harvested from posterior iliac crest and concentrated by SmartPrep to 6 mL of BMC. One step delivery system [2] OCL of talus 60 mL of BMA from ipsilateral iliac crest, concentrated by commercially available BMAC centrifuge system to obtain 4 mL of pluripotent cells [30] Tibial shaft nonunion Bone marrow aspirated from anterior iliac crest total of 300 mL then concentrated to 50 mL 18 ± 7 million BMAC injected into 60 noninfected atrophic nonunion of tibia. Follow up until union Radiographic union; healing time; volume of callus Patients who did not achieve union had significantly lower number of progenitor cells comparing to the 53 patients who achieved union. There was positive correlation between the volume of mineralized callus at 4 mo and the number and concentration of fibroblast colony-forming units in the graft; there was a negative correlation between the time needed to obtain union and the concentration of CFU in the graft Ⅳ Ismail et al [31] Long bone nonunion 40 mL of bone marrow was aspirated from posterior iliac crest and transferred into a container prefilled with 5000 U/mL of heparin. Aspirate was diluted with phosphate-buffered saline at a ratio of 1:1 and centrifuged at room temperature at 3000 rpm for 30 min. The collected buffy coat was washed and transferred into a culture flask containing Dulbecco's Modified Eagle Medium supplemented with 10% fetal bovine serum. Cells were incubated at 37 ℃ at 5% CO2 with a routine culture medium change every two to three days. Subculture was performed between 14-18 million BMSCs n (total) = 10. n = 5, treated with combination of 15 million BM-MSCs, 5 g/cm 3 (HA) granules and internal fixation. n = 5, control subjects were treated with iliac crest autograft, 5 g/cm 3 HA granules with internal fixation. Follow up = 12 mo VAS, LEFS, DASH score. Radiological assessments for union were conducted by a blinded radiologist using two radiological scoring systems: The Lane-Sandhu and Tiedeman radiological scores No significant differences in post-op pain between the two groups. The treatment group demonstrated initial radiographic and functional improvements. Statistically significant differences in functional scores were present during the first (P = 0.002), second (P = 0.005) and third (P = 0.01) month. Both groups achieved similar outcomes by the end of one year follow up Ⅲ compared to patients in the autograft group [33] . One study found a significantly lower number of progenitor cells in patients who did not achieve union as well as a negative correlation between the time needed to obtain union and the concentration of colony forming units in the graft [30] . Lastly, one study evaluated the efficacy of cBMA in the treatment of open tibia fractures and found adequate bone consolidation and bone callus formation in all patients [25] . Variation of cBMA application was seen amongst the studies evaluated. These methods utilized cBMA in isolation or in combination with DBM/rhBMP-2, freeze-dried allograft, or cancellous bone chips. Application of cBMA to the site of nonunion was accomplished by either fluoroscopic visualization or percutaneous injection.
cBMA in tendon repair
Five studies evaluating cBMA in tendon repair were included and summarized in Table 5 [34 -38] .
One study evaluated open Achilles tendon repair augmented with cBMA and reported excellent functional outcomes, early mobilization, normal range of motion, and no re-ruptures at a mean follow up of 29.7 mo [38] . One study evaluated the use of cBMA during rotator cuff repair and reported enhanced healing rates, improved quality of the repair surface on ultrasound and MRI, and a decreased risk of rerupture when compared to the control group [34] . The MSC content in rotator cuff tears was evaluated in one study, which demonstrated a moderate-to-severe reduction in content at the tendon-bone interface tuberosity relative to the control [35] . Lastly, one study showed that MSCs treated with insulin had an increase in tendon-specific markers, content of tendon specific proteins, and receptors on the cell surface compared with control cells [36] . None of the studies specifically described the method of cBMA injection.
DISCUSSION

cBMA in cartilage repair
Articular cartilage injury presents orthopedic surgeons with a difficult challenge as its inherent avascularity and poor healing potential can hinder its self-regenerative capacity. This poor repair capacity has been implicated in the development of post-traumatic osteoarthritis (PTOA) and osteochondral lesions (OCL). Traditional techniques for surgical stimulation of cartilage repair include microfracture and micropicking. These techniques penetrate the subchondral bone in order to stimulate blood flow and allow MSCs access to the cartilage defect. In addition, [34] Rotator cuff 150 mL BMA from iliac crest mixed with an anticoagulant solution (citric acid, sodium citrate, dextrose). MSCs were injected in the tendon at the junction between the bone and tendon (4 mL), and in the bone at the site of the footprint (8 mL [36] Rotator cuff MSCs were exposed to either insulin or tendoninducing growth factors or were left untreated to serve as a control. The BMA was overlaid onto a 17.5% sucrose gradient and centrifuged for 5 min at 1500 rpm (205 g), and the resulting pink middle layer was obtained. After the isolation of bone marrow, MSCs were exposed to a 1-time dose of 10-9-mol/L, 10-10-mol/L, 10-12-mol/L, or 10-13-mol/L insulin from bovine pancreas or were left untreated to serve as a control NS n = 11 patients undergoing arthroscopic RCR. After the determination of the optimal dose of insulin, MSCs were (1) exposed to the hormone insulin; (2) exposed to the growth factors IGF-1, bFGF, and GDF-5, which served as a positive control for MSCs' differentiation into a tendon; or (3) left untreated to serve as a negative control. In the growth factor group, MSCs were treated with a 1-time dose, 10 ng/ L, of IGF-1, bFGF, and GDF-5 or 10-10-mol/L insulin Cell count, gene expression, protein analysis, and immunocytochemical analysis. Confirmation of protein levels was verified on immunocytochemistry analysis by 4 independent evaluators blinded to group assignment MSCs treated with insulin showed increased gene expression of tendon-specific markers (P > 0.05), increased content of tendon-specific proteins (P > 0.05), and increased receptors on the cell surface (P > 0.05) compared with control cells. Histologic analysis showed a tendonlike appearance compared with the control cells Ⅲ Mazzocca et al [37] Rotator cuff Isolation 1: one 5 min centrifugation at 1500 rpm in which BMA was overlaid onto a 17.5% sucrose gradient in a 50-mL conical tube followed by extraction of CTPs in the fractional layer. First and second-generation ACI procedures, as well as mosaicplasty, have several concerns including donor site morbidity, cost, and lack of availability to all surgeons due to FDA restrictions. The inability of chondrocytes to self-regenerate and self-renew has directed surgeons to investigate alternative biologic augments in the traditional surgical treatment for cartilage defects. cBMA is a rich source of mesenchymal stem cells and has emerged as a treatment strategy to regenerate cartilage defects in OCL and PTOA.
Several in vivo models have demonstrated production of type II collagen and hyaline-like repair tissue when introducing MSCs to a cartilage defect, therefore the use of cBMA may provide further stimulation of chondrogenesis when addressing cartilaginous lesions [19] . There have been a number of studies evaluating the use of cBMA in cartilage regeneration and repair in the animal model. Saw et al [39] investigated the use of cBMA combined with hyaluronic acid in the treatment of full-thickness chondral defects in a goat model and reported hyaline regeneration after 24 wk. Fortier et al [40] evaluated the treatment of full-thickness cartilage defects with cBMA combined with microfracture in the equine model. Improvements in both macroscopic and histologic scores in tissue treated with cBMA were reported with MRI demonstrating an increase in defect filling and improved repair tissue integration with normal surrounding cartilage [40] . The current literature demonstrates the potential benefits of utilizing cBMA for the repair of cartilage injury in the clinical setting. Significant clinical improvement in functional scores was demonstrated with the use of cBMA in the treatment of full thickness cartilage injury, post-traumatic osteoarthritis, and osteochondral lesions. Improved clinical and histologic results were reported when cBMA was used as an adjunctive procedure with either microfracture or MACI in the treatment of full thickness chondral lesions [4, 6, 7] . On MRI, groups treated with cBMA demonstrated superior cartilage ingrowth with T2 values closer to that of superficial hyaline cartilage when compared to either a control scaffold or MACI alone [7, 10] . These positive results were also demonstrated when utilizing cBMA in the treatment of OCLs. Gobbi et al [18] compared with microfracture with cBMA in the treatment of OCLs and found that microfracture resulted in 65% normal IKDC at 2 years with decline to 27% at 5 years vs 100% normal at 2 years and no decline at 5 years for patients treated with cBMA. Buda et al [11] reported a higher presence of hyaline like values and lower incidence of fibrocartilage on T2 mapping in patients who received cBMA when compared to those who received ACI. Hannon et al [19] also demonstrated better T2 relaxation values with higher measurements of adjacent cartilage in patients treated with bone marrow stimulation (BMS) with cBMA than those treated with BMS alone. Surprisingly, these positive results were not translated as effectively when evaluating cBMA in the treatment of knee OA. Overall, studies demonstrated positive results with improved pain and clinical scores initially but after oneyear follow-up, there was no significant difference between groups receiving cBMA and those that did not.
cBMA in bone regeneration
Nonunion is a catastrophic failure of bone healing, which has gained increased attention over the last two decades. It is estimated that 5% to 10% of fractures will result in delayed union or nonunion resulting in prolonged treatment and repeated hospitalizations, longer rehabilitation protocols, and increased overall morbidity [41] . The financial burden posed by nonunion remains a challenge for orthopedic surgeons with a total estimated cost of these complications ranging between $23000 and $60000 per patient [42] . Numerous techniques of treating nonunion have been described in the literature including invasive interventions such as open reduction internal fixation with the use of bone graft or bone graft substitutes. Autologous cancellous bone graft derived from the iliac crest is still considered the gold standard graft option due to its high potentials of osteoconduction, osteoinduction, and osteogenesis. However, there is a limit to the amount of bone graft from iliac crest donor site that can be harvested in the reconstruction of large osseous defects. In addition, there are disadvantages of chronic donor site pain, cosmetic concern, and nerve injury, which have been documented in the literature [33] . The use of cBMA as an adjunctive procedure has gained attention in the treatment of nonunions [30] . The current literature demonstrates faster healing with greater than 94% union rate when using cBMA combined with allograft compared with conventional autologous cancellous bone graft [33] . Ismail et al [31] reported similar union rates and outcomes when comparing cBMA and iliac crest autograft. The benefits of cBMA as an adjunctive therapy has also been demonstrated in the treatment of upper extremity long bone nonunion. Garnavos et al [27] described successfully using a minimal invasive approach by injecting cBMA to address humeral diaphyseal fractures, thereby avoiding potential complications associated with the conventional compression plating technique for treating humeral nonunions. Hernigou et al [29] utilized the same minimally invasive technique to treat diabetic ankle fractures nonunion. The diabetic population poses a challenge for orthopedic surgeons with well-documented increased complications and increased time to bony union.
Hernigou et al [29] also reported a union rate of 82.1%
with minimal complications in patients who received cBMA compared to a union rate of 62.3% with major complications in patients who received iliac bone graft alone. Several studies evaluated the effect of BMA concentration on functional outcomes when treating long bone nonunions. Hernigou et al [30] demonstrated that improved time to union with the use of cBMA was potentially related to the number of progenitors in the graft. The amount of bone healing may be directly related to the concentration of cells and the time to union may be indirectly related to the number of cells [30] . This finding was also supported by Guimaraes et al [28] demonstrating that grafts used in patients whom treatment failed contained significantly lower number of total nucleated cells. Bastos Filho et al [25] compared using cBMA vs whole volume BMA reporting no significant difference in time to union and patient satisfaction score. Although no significant difference was reported, this may be attributed to the small sample size in the cBMA group (n = 2) and minimal follow up. In addition, this study highlighted that unprocessed cBMA contains larger volume and fatty content in the graft increasing the risk of pulmonary embolism, therefore the smaller volume of cBMA may in fact be a safer alternative.
cBMA in tendon repair
Tendon injuries typically result from repetitive motions or overuse and can be difficult to treat as many patients either present late or after a prolonged period of nonoperative management making treatment challenging due to the chronicity of the injury. It has been well documented that delayed presentation of rotator cuff tears decreases the MSC content and healing potential in patients [35] . A study by Hernigou et al [35] reported a significant reduction in the number of MSCs at the tendon-bone interface of the greater tuberosity in patients with a rotator cuff injury. In addition, they found that the severity of the decrease in MSC content correlated to increasing patient age, delay between onset of symptoms and surgery, fatty infiltration stage of muscle, and the number of involved tendons [35] . It has been demonstrated that MSCs have the potential to develop into tenocytes and can be a source of growth factors to establish an environment conducive to tendon tissue regeneration. MSCs in the form of cBMA have been shown to improve the strength and quality of tissue formed when used in tendon repair [34, 35, 38] . The current literature has demonstrated that the addition of cBMA can help to heal tendon injuries and at times may decrease the healing time and rate of rerupture. Hernigou et al [35] reported enhanced healing and improved quality of the repair surface on ultrasound and MRI in patients receiving cBMA during rotator cuff repair. They reported that 100% of the rotator cuff repairs healed by six months compared to 67% in the control group. Furthermore, 87% of the study group had an intact rotator cuff repair compared to 44% of the control at ten year follow up indicating superior outcomes in the longer term [34] . The benefits of cBMA in tendon repair have also been demonstrated in the Achilles tendon model. Stein et al [38] reported excellent results with no re-ruptures, decreased calf atrophy, early mobilization, a 92% return to sport, and better ankle range of motion in patients receiving adjunctive cBMA during Achilles tendon repair compared to those who received no additional treatment.
One of the difficulties in analyzing BMA literature is the variable methods of harvesting, preparing, and concentrating cBMA. Mazzocca et al [37] devised a novel technique for harvesting BMA in patients undergoing rotator cuff repair with no donor site morbidity. BMA was harvested through the anchor tunnel of the humeral head during routine arthroscopic rotator cuff repair.
No additional complications during the procedure, no significant delay in the procedure, and no difference in functional patient outcomes were reported when using this harvest technique [37] . Lee et al [43] studied the use of two different concentrations of allogenic cBMA in patients with lateral epicondylitis. They found no significant differences in the changes of elbow pain and performance between the two groups on follow up visits but they did note faster pain improvement and an earlier plateau of performance scores in the group that received a higher concentration of MSCs [43] . Lastly, Mazzocca et al [36] showed that MSCs treated with insulin showed statistically significant increase in gene expression of tendon-specific markers, increase in content of tendonspecific proteins, and increase in receptors on the cell surface. Therefore, these studies demonstrate that there are many factors that can increase the potential for tenocyte differentiation and enhanced tendon repair and regeneration.
Level of evidence
Although the literature highlights the potential benefit of cBMA as either a primary or adjunctive treatment strategy in the treatment of cartilaginous lesions, bony defects, and tendon injury, the majority of these studies were of clinical level of evidence Ⅲ or Ⅳ. This review demonstrates the need for future randomized clinical trials with larger numbers of subjects and standardization of harvesting and application. Although several studies evaluated the effect of cell concentration on healing potential, an effective therapeutic range has yet to be established for each tissue environment.
Summary of MSC mechanism
Adult BMSCs have two primary functions: (1) to differentiate into distinctive end-stage cell types such as bone, cartilage, and tendon; and (2) to secrete bioactive macromolecules that are both immunoregulatory and regenerative [44] . Every cell has a half-life with a turnover sequence mechanism that gives rise to the phenotypes in complex tissues. This allows for both replacement of cells, as well as, the capacity for differentiation into bone, cartilage, and tendon. BMSCs also have characteristic markers of pericytes, which are smooth muscle vascular support cells that may play an important role in stem cell differentiation [44, 45] . MSCs also demonstrate trophic activity through secretion of both cytokines and growth factors [46] . The intrinsic secretory activity of MSCs affords a regenerative environment for the repair of injured or damaged tissues [44] . Tissue-specific scaffolds have also been utilized in tissue engineering to reform tissues when MSCs are implanted into different tissue sites. The capacity for cell regeneration and repair relies on several additional factors including patient age, extent of injury/ damage, and the functional ability of MSCs to grow and repair. Tissue engineering allows for the manipulation of both the delivery of MSCs to targeted tissue sites and the microenviroment for which cells grow in order to enhance differentiation [44] . Future investigations will continue to focus on harnessing the therapeutic potential of MSCs in tissue specific environments to enhance regeneration and repair of cartilage, bone, and tendon.
Conclusion
The current literature demonstrates the potential benefits of utilizing cBMA for the repair of cartilaginous lesions, bony defects, and tendon injuries in the clinical setting. The studies have demonstrated using cBMA as an adjunctive procedure can result in cartilage healing similar to that of native hyaline tissue, faster time to bony union, and a lower rate of tendon re-rupture. This systematic review also demonstrates discrepancies between the literature with regards to various methods of centrifugation, variable cell count concentrations, and lack of standardized outcome measures. Although several studies evaluated the effect of cell concentration on healing potential, an effective therapeutic range has yet to be established for each tissue environment. Future studies should attempt to examine the integral factors necessary for tissue regeneration and renewal including stem cells, growth factors and a biologic scaffold.
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